On 1 March 2017 the RCP’s Inflammatory Bowel Disease (IBD) Audit Programme successfully transitioned the biologics audit to the UK IBD Registry.
The IBD Audit Programme has over the last 10 years, observed many improvements in the care of people with IBD. Patients with IBD are now much better off than they were 10 years ago – there are now more specialist IBD nurses, pharmacists and dietitians seeing more people with IBD. Mortality in hospital has halved since the start of collecting audit data in 2006.
The provision and care of people receiving biological therapies has improved and they are generally safe and effective – in particular the new biosimilars that have come to the market in the last few years.
Although the IBD Audit Programme has demonstrated how widespread data collection has encouraged and driven improvements over time there are still many aspects of care that still need to be improved. The transition to the IBD UK Registry is the start of a new phase of ongoing data collection and reporting. We encourage hospital teams to keep participating to continue to build on the successes of the audit programme.
The work of the IBD audit programme is clinically led by Dr Ian Arnott, consultant gastroenterologist at NHS Lothian.
In 2017 the IBD programme will be continuing to support quality improvement through a number of initiatives.
The IBD programme is guided by the multidisciplinary IBD programme steering group, which is a collaborative partnership between gastroenterologists (the British Society of Gastroenterology), colorectal surgeons (the Association of Coloproctology of Great Britain and Ireland), patients (Crohn's and Colitis UK), physicians (the Royal College of Physicians), nurses (the Royal College of Nursing), pharmacists (the Royal Pharmaceutical Society), dietitians (the British Dietetic Association) and paediatric gastroenterologists (the British Society of Paediatric Gastroenterology, Hepatology and Nutrition).